Literature DB >> 16825367

Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.

Andrea Francesconi1, Miki Kasai, Ruta Petraitiene, Vidmantas Petraitis, Amy M Kelaher, Robert Schaufele, William W Hope, Yvonne R Shea, John Bacher, Thomas J Walsh.   

Abstract

Bronchoalveolar lavage (BAL) is widely used for evaluation of patients with suspected invasive pulmonary aspergillosis (IPA). However, the diagnostic yield of BAL for detection of IPA by culture and direct examination is limited. Earlier diagnosis may be facilitated by assays that can detect Aspergillus galactomannan antigen or DNA in BAL fluid. We therefore characterized and compared the diagnostic yields of a galactomannan enzyme immunoassay (GM EIA), quantitative real-time PCR (qPCR), and quantitative cultures in experiments using BAL fluid from neutropenic rabbits with experimentally induced IPA defined as microbiologically and histologically evident invasion. The qPCR assay targeted the rRNA gene complex of Aspergillus fumigatus. The GM EIA and qPCR assay were characterized by receiver operator curve analysis. With an optimal cutoff of 0.75, the GM EIA had a sensitivity and specificity of 100% in untreated controls. A decline in sensitivity (92%) was observed when antifungal therapy (AFT) was administered. The optimal cutoff for qPCR was a crossover of 36 cycles, with sensitivity and specificity of 80% and 100%, respectively. The sensitivity of qPCR also decreased with AFT to 50%. Quantitative culture of BAL had a sensitivity of 46% and a specificity of 100%. The sensitivity of quantitative culture decreased with AFT to 16%. The GM EIA and qPCR assay had greater sensitivity than culture in detection of A. fumigatus in BAL fluid in experimentally induced IPA (P+/-0.04). Use of the GM EIA and qPCR assay in conjunction with culture-based diagnostic methods applied to BAL fluid could facilitate accurate diagnosis and more-timely initiation of specific therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825367      PMCID: PMC1489482          DOI: 10.1128/JCM.02693-05

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

Authors:  J Maertens; J Verhaegen; K Lagrou; J Van Eldere; M Boogaerts
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model.

Authors:  M J Becker; S de Marie; D Willemse; H A Verbrugh; I A Bakker-Woudenberg
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

5.  Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients.

Authors:  D Caillot; L Mannone; B Cuisenier; J F Couaillier
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

6.  Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients.

Authors:  E Jantunen; P Ruutu; A Piilonen; L Volin; T Parkkali; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2000-10       Impact factor: 5.483

Review 7.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

8.  Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis.

Authors:  M Kami; T Fukui; S Ogawa; Y Kazuyama; U Machida; Y Tanaka; Y Kanda; T Kashima; Y Yamazaki; T Hamaki; S Mori; H Akiyama; Y Mutou; H Sakamaki; K Osumi; S Kimura; H Hirai
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

9.  Epidemiology of invasive fungal infections in bone marrow transplantation. EORTC Invasive Fungal Infections Cooperative Group.

Authors:  R De Bock
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

10.  Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.

Authors:  T J Walsh; K Garrett; E Feurerstein; M Girton; M Allende; J Bacher; A Francesconi; R Schaufele; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  22 in total

1.  Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.

Authors:  Martina Lengerova; Iva Kocmanova; Zdenek Racil; Kristyna Hrncirova; Sarka Pospisilova; Jiri Mayer; Laura K Najvar; Nathan P Wiederhold; William R Kirkpatrick; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

2.  Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity.

Authors:  Jorien D'Haese; Koen Theunissen; Edith Vermeulen; Hélène Schoemans; Greet De Vlieger; Liesbet Lammertijn; Philippe Meersseman; Wouter Meersseman; Katrien Lagrou; Johan Maertens
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

3.  Molecular diagnostics for invasive fungal infections: a call for refinement and implementation.

Authors:  Gary W Procop
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

Review 4.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.

Authors:  Kimberly A Such; Vidmantas Petraitis; Ruta Petraitiene; Gittel E Strauss; Patriss-Wais Moradi; Thomas J Walsh
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

6.  High-throughput identification and quantification of Candida species using high resolution derivative melt analysis of panfungal amplicons.

Authors:  Tasneem Mandviwala; Rupali Shinde; Apoorv Kalra; Jack D Sobel; Robert A Akins
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

7.  Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR.

Authors:  Andrea Francesconi; Miki Kasai; Susan M Harrington; Mara G Beveridge; Ruta Petraitiene; Vidmantas Petraitis; Robert L Schaufele; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2008-03-19       Impact factor: 5.948

8.  Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance.

Authors:  E Fréalle; K Decrucq; F Botterel; B Bouchindhomme; D Camus; E Dei-Cas; J M Costa; I Yakoub-Agha; S Bretagne; L Delhaes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-02       Impact factor: 3.267

Review 9.  Evaluation of respiratory disease.

Authors:  Sofya Tokman; Laurence Huang
Journal:  Clin Chest Med       Date:  2013-04-15       Impact factor: 2.878

10.  Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis.

Authors:  Randall Hayden; Stanley Pounds; Katherine Knapp; Ruta Petraitiene; Robert L Schaufele; Tin Sein; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.